Second Quarter 2026
Filed Aug 10, 2026Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
The supplied release excerpt reports broad clinical and pipeline progress, including initiation of a pivotal BHV-1300 trial and multiple anticipated second-half 2026 data milestones, but it does not include the financial-results tables or reported financial metrics needed to assess quarterly operating performance.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|
What drove it
- BHV-1300 1000 mg administered weekly subcutaneously achieved mean reductions of pathogenic TSHR-IgG1 autoantibodies of greater than 80% by week 12 in patients with Graves’ hyperthyroidism.
- Among BHV-1300 study participants with elevated thyroid hormones despite concurrent anti-thyroid drug therapy, normalization of free T4 occurred at a median of 3 weeks and normalization of free T3 occurred at a median of 5 weeks after the first administration.
- BHV-1400 achieved mean reductions of pathogenic Gd-IgA1 of greater than 60% within 48 hours and approximately 70% within the first month of dosing in the ongoing IgAN study.
- The Company initiated a pivotal Phase 3 study of BHV-1300 in Graves’ disease and expects to initiate a pivotal study of BHV-1400 in IgAN in 2H 2026.
- In an idiopathic generalized epilepsy proof-of-concept study, median time to the second generalized tonic-clonic seizure was 141 days with opakalim versus 47 days with placebo.
- Updated focal-epilepsy open-label extension data showed that 54% of participants achieved a ≥50% reduction in seizure frequency over any consecutive six-month treatment period (n>100).
- Enrollment is complete in the Phase 2 obesity study of taldefgrobep alfa, and first-in-human dosing commenced for BHV-8100.
Concerns
- The supplied excerpt does not contain the financial-results tables, preventing assessment of revenue, operating expenses, net loss, cash use, liquidity, or quarterly changes.
- Key program catalysts remain prospective, including topline results from the Phase 2/3 RISE3 trial in focal epilepsy expected during 2H 2026.
- The planned pivotal study for BHV-1400 in IgAN is expected to initiate in 2H 2026 rather than already being underway.
- BHV-1530 clinical activity remains from an ongoing Phase 1, open-label, dose-escalation study, with a further data update planned for ESMO Congress 2026.
What to watch
- Topline results for the first Phase 2/3 opakalim study in focal epilepsy expected in 2H 2026.
- Topline Phase 2 obesity data for taldefgrobep alfa expected during 2H 2026.
- Initiation of the pivotal BHV-1400 study in IgAN expected in 2H 2026.
- New Phase 1 BHV-1530 data planned for presentation at ESMO Congress 2026.
- Advancement of enrollment in the global pivotal Phase 2/3 trial of BHV-8000 in early Parkinson’s disease.
Analysis
Biohaven’s supplied second-quarter release excerpt is centered on clinical execution rather than reported financial performance. The principal advancement is BHV-1300, for which the Company initiated a pivotal Phase 3 trial in Graves’ disease following Phase 1b data showing mean reductions of pathogenic TSHR-IgG1 autoantibodies of greater than 80% by week 12. The release also reports thyroid-hormone normalization timing in participants receiving concurrent anti-thyroid therapy and describes the program as safe and well-tolerated through 12 weeks of dosing.
The extracellular-degrader portfolio is the core demand and value driver discussed in the release. BHV-1400 in IgAN achieved reported pathogenic Gd-IgA1 reductions of greater than 60% within 48 hours and approximately 70% within the first month of dosing. The Company linked these reductions to increases in eGFR, decreases in spot UPCR, and resolution of hematuria, while stating there were no clinically significant reductions in other immunoglobulins. A pivotal BHV-1400 study is expected to initiate in 2H 2026, making execution against that stated timeline a central upcoming event.
Opakalim remains the other major near-term program. The release reports a 141-day median time to second generalized tonic-clonic seizure with opakalim versus 47 days with placebo in the idiopathic generalized epilepsy proof-of-concept study. It also cites a ≥50% seizure-frequency reduction for 54% of participants in the focal-epilepsy open-label extension dataset. The pivotal focal-epilepsy RISE3 topline readout is expected during 2H 2026, and that event will be the most direct test of the clinical narrative described in this release.
Pipeline activity broadened beyond the two lead areas. Enrollment is complete in the Phase 2 obesity study of taldefgrobep alfa, with topline data expected during 2H 2026. BHV-1530 Phase 1 data are planned for ESMO Congress 2026, the Company announced a clinical supply agreement with Regeneron for a BHV-1530 and Libtayo combination, and first-in-human dosing began for BHV-8100. Enrollment also continues in the Phase 2/3 BHV-8000 study in early Parkinson’s disease.
No revenue, expense, margin, earnings, cash-flow, balance-sheet, or capital-allocation figures appear in the supplied excerpt. As a result, the release does not permit a financial assessment of operating leverage, cash runway, quarterly cash consumption, funding needs, or capital returns. There is also no previous-quarter outlook supplied, so no actual-versus-prior-guidance comparison can be made.
Management, verbatim
What excites me most about Biohaven today is that we're no longer talking about scientific promise—we're watching new therapeutic approaches begin to work in patients.
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven
Across studies to date, opakalim has consistently demonstrated the potential to deliver meaningful seizure reduction with a differentiated tolerability profile from existing therapies.
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven
Not in the filing
stated, not guessed- Total revenue and revenue comparisons
- Segment revenue and segment comparisons
- GAAP gross profit or gross margin
- GAAP operating income or loss
- GAAP net income or loss
- GAAP earnings or loss per share
- Non-GAAP gross margin, operating income or loss, net income or loss, and earnings or loss per share
- Research and development expense
- Selling, general and administrative expense
- Operating cash flow
- Free cash flow
- Cash, cash equivalents, restricted cash, marketable securities, or other liquidity figures
- Debt and other balance-sheet figures
- Share repurchases, dividends, or other capital-return figures
- Financial revenue, expense, margin, tax-rate, or other financial guidance
- Prior-quarter financial results
- Prior-year financial results
- Previous-quarter outlook for actual-versus-guidance comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.